Filing Analysis
Regulation FD Disclosure
Filed May 07, 2026
LOW
Whitehawk Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release and filed under Item 2.02 of Form 8-K.
Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Press release issued on May 7, 2026
- Filing signed by Chief Financial Officer Scott Giacobello
- Information is furnished under Item 2.02 and not deemed 'filed' for Section 18 liability
Other SEC Filing
Filed Mar 12, 2026
LOW
Whitehawk Therapeutics, Inc. (WHWK) filed an 8-K on March 12, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The results were disclosed via a press release attached as Exhibit 99.1. This filing is a standard disclosure under Item 2.02.
Key Facts
- Company reported results for the fiscal year ended December 31, 2025.
- The report was filed on March 12, 2026.
- The filing was signed by Scott Giacobello, Chief Financial Officer.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.